Fibroblast growth factor antagonists
US5252718A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 27, 1992 |
| Grant date | Oct 12, 1993 |
| Priority date | — |
| Expiry date | Apr 27, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antagonists to basic fibroblast growth factor, a 146 amino acid residue polypeptide, are produced. These antagonists are generally between 10 and 45 residues in length and are characterized by their ability to interact with the FGF receptor and/or inhibit and therefore modulate endothelial and other cell growth in vitro and also in vivo. These antagonists includes the sequence of bovine basic FGF(106-115), namely Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr or a sequence having equivalent residues substituted therein. These peptides are also antagonistic to acidic FGF and other members of the family of FGF peptides. They are effective to combat FGF-promoted mitosis in melanomas and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.